BioXcel Therapeutics (BTAI) Tops Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
UPDATE: SunTrust Starts BioXcel Therapeutics (BTAI) at Buy
November 12, 2019 4:31 AM EST(Updated - November 12, 2019 7:26 AM EST)
(updated to add analyst comments)
SunTrust analyst Robyn Karnauskas initiates coverage on BioXcel Therapeutics (NASDAQ: BTAI) with a Buy rating and a price target of $24.00.
The analyst commented, "BioXcel's lead asset BXCL501 is in... More
